Literature DB >> 23864387

Insulin-like growth factor-I receptor is suppressed through transcriptional repression and mRNA destabilization by a novel energy restriction-mimetic agent.

Po-Chen Chu1, Samuel K Kulp, Ching-Shih Chen.   

Abstract

Insulin-like growth factor-I receptor (IGF-IR) represents one of the major targets by which dietary or chemically induced energy restriction mediates chemopreventive effects in animal tumor models. However, the mechanism underlying this cellular response remains unclear. In the course of investigating the suppressive effect of the energy restriction-mimetic agent CG-5 on IGF-IR expression in prostate cancer cells, we identified a novel posttranscriptional mechanism by which the RNA-binding protein human antigen R (HuR) regulates IGF-IR expression through messenger RNA (mRNA) stabilization. Previously, we demonstrated that Sp1 and HuR proteins were concomitantly targeted for ubiquitin-dependent degradation by β-transducin repeat-containing protein in response to CG-5. Although this loss of Sp1 expression contributed to CG-5-mediated IGF-IR downregulation, enforced specific protein 1 (Sp1) expression could only partially protect cells from the drug effect. The small interfering RNA-mediated silencing of HuR suppressed IGF-IR expression by reducing mRNA stability, whereas ectopic HuR expression increased IGF-IR mRNA stability and protein expression and, when coexpressed with Sp1, blocked CG-5-mediated IGF-IR ablation. RNA pull-down and immunoprecipitation analyses indicated that HuR selectively bound to the distal region of the IGF-IR 3' untranslated region (UTR), whereas no interaction with the 5'UTR was noted. Evaluation of a series of truncated HuR mutants revealed that the RNA recognition motifs (RRM2 and RRM3) were involved in IGF-IR 3'UTR binding and the consequent increase in IGF-IR mRNA stability. Although these data contrast with a previous report that HuR acted as a translation repressor of IGF-IR mRNA through 5'UTR binding, our finding is consistent with the reported oncogenic role of HuR in conferring stability to target mRNAs encoding tumor-promoting proteins.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23864387      PMCID: PMC3845891          DOI: 10.1093/carcin/bgt251

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  54 in total

Review 1.  Defining the pathway to insulin-like growth factor system targeting in cancer.

Authors:  Steven A Rosenzweig; Hanudatta S Atreya
Journal:  Biochem Pharmacol       Date:  2010-06-23       Impact factor: 5.858

2.  Alterations in RNA-binding activities of IRES-regulatory proteins as a mechanism for physiological variability and pathological dysregulation of IGF-IR translational control in human breast tumor cells.

Authors:  Zheng Meng; Nateka L Jackson; Hyoungsoo Choi; Peter H King; Peter D Emanuel; Scott W Blume
Journal:  J Cell Physiol       Date:  2008-10       Impact factor: 6.384

Review 3.  Implications of insulin-like growth factor-I for prostate cancer therapies.

Authors:  Satoko Kojima; Masahiko Inahara; Hiroyoshi Suzuki; Tomohiko Ichikawa; Yuzo Furuya
Journal:  Int J Urol       Date:  2008-12-05       Impact factor: 3.369

Review 4.  Diverse molecular functions of Hu proteins.

Authors:  M N Hinman; H Lou
Journal:  Cell Mol Life Sci       Date:  2008-10       Impact factor: 9.261

5.  Energy restriction as an antitumor target of thiazolidinediones.

Authors:  Shuo Wei; Samuel K Kulp; Ching-Shih Chen
Journal:  J Biol Chem       Date:  2010-01-21       Impact factor: 5.157

6.  Thiazolidinediones mimic glucose starvation in facilitating Sp1 degradation through the up-regulation of beta-transducin repeat-containing protein.

Authors:  Shuo Wei; Hsiao-Ching Chuang; Wan-Chi Tsai; Hsiao-Ching Yang; Shiuh-Rong Ho; Andrew J Paterson; Samuel K Kulp; Ching-Shih Chen
Journal:  Mol Pharmacol       Date:  2009-04-16       Impact factor: 4.436

7.  Reduced susceptibility to two-stage skin carcinogenesis in mice with low circulating insulin-like growth factor I levels.

Authors:  Tricia Moore; Steve Carbajal; Linda Beltran; Susan N Perkins; Shoshana Yakar; Derek Leroith; Stephen D Hursting; John Digiovanni
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

8.  Dietary energy balance modulates signaling through the Akt/mammalian target of rapamycin pathways in multiple epithelial tissues.

Authors:  Tricia Moore; Linda Beltran; Steve Carbajal; Sara Strom; Jeanine Traag; Stephen D Hursting; John DiGiovanni
Journal:  Cancer Prev Res (Phila)       Date:  2008-03-31

Review 9.  Minireview: posttranscriptional regulation of the insulin and insulin-like growth factor systems.

Authors:  Eun Kyung Lee; Myriam Gorospe
Journal:  Endocrinology       Date:  2009-12-23       Impact factor: 4.736

10.  The RNA-binding protein HuR regulates DNA methylation through stabilization of DNMT3b mRNA.

Authors:  Isabel López de Silanes; Myriam Gorospe; Hiroaki Taniguchi; Kotb Abdelmohsen; Subramanya Srikantan; Miguel Alaminos; María Berdasco; Rocío G Urdinguio; Mario F Fraga; Filipe V Jacinto; Manel Esteller
Journal:  Nucleic Acids Res       Date:  2009-03-06       Impact factor: 16.971

View more
  3 in total

1.  Cooperative Repression of Insulin-Like Growth Factor Type 2 Receptor Translation by MicroRNA 195 and RNA-Binding Protein CUGBP1.

Authors:  Yuan Zhang; Yun Zhang; Lan Xiao; Ting-Xi Yu; Jun-Zhe Li; Jaladanki N Rao; Douglas J Turner; Myriam Gorospe; Jian-Ying Wang
Journal:  Mol Cell Biol       Date:  2017-09-12       Impact factor: 4.272

Review 2.  Post-transcriptional regulation of cytokine and growth factor signaling in cancer.

Authors:  Irina Vlasova-St Louis; Paul R Bohjanen
Journal:  Cytokine Growth Factor Rev       Date:  2016-12-02       Impact factor: 7.638

3.  Downregulation of HuR Inhibits the Progression of Esophageal Cancer through Interleukin-18.

Authors:  Xiaohui Xu; Cheng Song; Zhihua Chen; Chenxiao Yu; Yi Wang; Yiting Tang; Judong Luo
Journal:  Cancer Res Treat       Date:  2017-02-24       Impact factor: 4.679

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.